All-trans retinoic acid rapidly decreases cathepsin G synthesis and mRNA expression in acute promyelocytic leukemia

Leukemia

Volumn 10, Issue 1, 1996, Pages 95-101

  Seale, J ^a   Delva, L ^a   Renesto, P ^c   Balitrand, N ^a   Dombret, H ^a   Scrobohaci, M L ^b   Degos, L ^a   Paul, P ^a   Chomienne, C ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b Laboratoire Central d'Hematologie   (France)

^c INSTITUT PASTEUR   (France)

Author keywords

Acute promyelocytic leukemia; Cathepsin G; Differentiation; Hemostasis; Retinoic acid

Indexed keywords

CATHEPSIN G; MESSENGER RNA; RETINOIC ACID; SERINE PROTEINASE;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; BLOOD CLOTTING DISORDER; CELL DIFFERENTIATION; CELL LINE; CLINICAL ARTICLE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RETINOIC ACID SYNDROME;

EID: 0030051723     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. de The H et al. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 1990; 347: 558-561.
2. Alcalay M et al. Translocation breakpoint of acute promyelocytic leukemia lies within the retinoic acid receptor alpha locus. Proc Natl Acad Sci USA 1991; 88: 1977-1981.
3. Borrow J, Goddard AD, Sheer D, Solomon E. Molecular analysis ot acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science 1990; 249: 1577-1580.
4. Castaigne S et al. A PML/retinoic acid receptor alpha fusion transcript is constantly detected by RNA-based polymerase chain reaction in acute promyelocytic leukemia. Blood 1992; 79: 3110-3115.
5. de The H et al. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR Cell 1991; 66: 675-684.
6. Chomienne C et al. All-trans retinoic acid in acute promyelocytic ieukemias. II. In vitro studies: structure-function relationship. Blood 1990; 76: 1710-1716.
7. Huang ME et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567-571.
8. Castaigne S et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990; 76: 1704-1709.
9. Warrell RP Jr et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). New Engl J Med 1991; 324: 1385-1393.
10. Wu X et al. Four years experience with the treatment of all-trans retinoic acid in acute promyelocytic leukemia. Am J Hematol 1993; 43: 183-189.
11. Warrell RP Jr et al. Treatment of acute promyelocytic leukemia with all-trans retinoic acid, an update of the New York experience. Leukemia 1994; 8: 929-933.
12. Miller WH Jr et al. Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-alpha fusion mRNA. Blood 1993; 82: 1689-1694.
13. Fenaux P et al. and the European APL 91 Group. Effect of all trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. Blood 1993; 82: 3241-3249.
14. Fenaux P et al. All-trans retinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. Blood 1992; 80: 2176-2181.
15. Tallman MS, Kwan H. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 1992; 79: 543-548.
16. Dombret H et al. Plasma free serine protease activity in patients with acute promyelocytic leukemia: effect of all-trans retinoic acid therapy. Blood 1993; 82: 249a (abstr.).
17. Plow EF. The contribution of leukocyte proteases to fibrinolysis. Blut 1986; 53: 1-9.
18. Sakata Y et al. The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia. Blood 1991; 77: 1949-1957
19. Petersen L, Bjorn SE, Nordtang O. Effect of leukocyte proteinases on tissue factor pathway inhibitor. Thromb Haemost 1992; 67: 537-541.
20. Pratt CW, Tobin RB, Chuch FC. Interaction of heparin cofactor II with neutrophil elastase and cathepsin G. J Biol Chem 1990; 265: 6092-6097.
21. Selak MA, Chignard M, Smith JB. Cathepsin C is a strong platelet agonist released by neutrophils. Biochem J 1988; 251: 293-299.
22. Peterson MW. Neutrophil cathepsin G increases transendothelial albumin flux. J Lab Clin Med 1989; 113: 297-308.
23. Rochat T, Casale J, Hunninghake G, Petersen M. Neutrophil cathepsin G increases the permeability of cultured type II pneumocytes. Am J Physiol 1988; 255: 603-611.
24. Frankel SR et al. The 'retinoic acid syndrome' in acute promyelocytic leukemia. Ann Intern Med 1992; 117: 292-296.
25. Campbell EJ, Silverman EK, Campbell MA: Elastase and cathepsin G of human monocytes. Quantification of cellular content, release in response to stimuli, and heterogeneity in elastase-mediated proteolytic activity. J Immunol 1989; 143: 2961-2968.
26. Hanson RD et al. Developmental regulation of the human cathepsin G gene in myelomonocytic cells. J Biol Chem 1990; 265: 1524-1530.
27. Bennett JM et al. Proposals for the classification of the acute leukaemias. French-American-Britain (FAB) co-operative group. Br J Haematol 1976; 33: 451-458.
28. Lanotte M et al. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 1991; 77: 1080-1086.
29. Robertson KA, Emami B, Collins SJ. Retinoic acid-resistant HL-60R cells harbor a point mutation in the retinoic acid receptor ligand-binding domain that confers dominant negative activity. Blood 1992, 80: 1885-1889.
30. Renesto P, Kadiri C, Chignard M. Combined activation of platelets by cathepsin G and platelet activating factor, two neutrophil-derived agonists. Br J Haematol 1992; 80: 205-213.
31. Dani C et al. Extreme instability of myc mRNA in normal and transformed human cells. Proc Natl Acad Sci USA 1984; 81: 7046-7050.
32. Yoshimura K, Crystal RG. Transcriptional and post-transcriptional modulation of human neutrophil elastase gene expression. Blood 1992; 79: 2733-2744.
33. Labbaye C et al. Regulation of myeloblastin messenger RNA expression in myeloid leukemia cells treated with all-trans retinoic acid. Blood 1993; 81: 475-481.
34. Ferrer Lopez P et al. Heparin inhibits neutrophil-induced platelet activation via cathepsin G. J Lab Clin Med 1992, 119: 231-239.
35. Maison CM, Villiers CI, Colomb MG. Proteolysis of C3 on U937 cell plasma membranes. Purification of cathepsin G. J Immunol 1991; 147: 921-926.